Shares of Acasti Pharma (NASDAQ:ACST) are jumping more than 25% higher today after a major investment firm initiated coverage. ACST stock has declined by more than 50% year to date (YTD), vastly ...
Acasti Pharma (ACST) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...
Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...
Today’s late-stage pharmaceutical companies remind me of the old oil wildcatters from the 1920s. They spend a ton of money hyping a study, as wildcatters would a prospect. Then investors wait ...
Acasti Pharma (NASDAQ:ACST) is a classic example of the extreme volatility of small-cap biotech stocks. It was only in late December that the shares were fetching $2.87, up from $1 a year earlier. But ...
Shares of Acasti Pharma (NASDAQ:ACST) are jumping more than 25% higher today after a major investment firm initiated coverage. ACST stock has declined by more than 50% year to date (YTD), vastly ...
Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results